IPHA sentiment intelligence

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone

Neutral 50/100

Event

Earnings

Published

13 Jul 2026 12:30

Source

Market source

Innate Pharma (IPHA) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Investment Intensifies - Growth Acceleration Report

Tone

Neutral 50/100

Event

Earnings

Published

06 Jul 2026 19:48

Source

DonanımHaber

Innate Pharma(IPHA) Stock Options Chain | Quotes & News

This article provides the stock options chain, quotes, and news for Innate Pharma (IPHA). It serves as a resource for investors interested in the company's financial performance and market derivatives. The content helps users access relevant financial data and recent updates for

Tone

Neutral 50/100

Event

Market update

Published

06 Jul 2026 20:10

Source

Moomoo

Q1 2026 Innate Pharma SA Corporate Sales Call Transcript

This document is a transcript of Innate Pharma SA's Q1 2026 Corporate Sales Call, which took place on May 13, 2026, at 11:30 AM GMT. The call covered the company's business and financial results for the first quarter of 2026, with a question-and-answer session following the initi

Tone

Neutral 50/100

Event

Earnings

Published

02 Jul 2026 14:40

Source

GuruFocus

Price to earnings forward of Innate Pharma SA Class A – EURONEXT:IPH

This article provides the "Price to earnings forward" value for Innate Pharma SA Class A (EURONEXT:IPH) as presented on TradingView. The page indicates the market is closed with no trades. It also highlights the data sources and copyright information for the financial data presen

Tone

Neutral 50/100

Event

Earnings

Published

30 Jun 2026 16:40

Source

TradingView

Enterprise value to EBITDA forward of Innate Pharma SA Class A – EURONEXT:IPH

This article displays the enterprise value to EBITDA forward for Innate Pharma SA Class A (EURONEXT:IPH) on TradingView. It appears to be a financial data snippet rather than a full analytical report, showing the period, value, and change percentages for this metric. The main con

Tone

Neutral 50/100

Event

Market update

Published

28 Jun 2026 15:39

Source

TradingView

Price to sales forward of Innate Pharma SA Class A – EURONEXT:IPH

This page provides financial information for Innate Pharma SA Class A (EURONEXT:IPH), specifically focusing on its Price to Sales Forward metric. The content highlights that the market was closed with no trades at the time of viewing, indicating a static financial snapshot for th

Tone

Neutral 50/100

Event

Market update

Published

26 Jun 2026 13:10

Source

TradingView

Price to book forward of Innate Pharma SA Class A – EURONEXT:IPH

The page displays information regarding the "Price to book forward" for Innate Pharma SA Class A (EURONEXT:IPH). The article is primarily a data placeholder from TradingView, indicating financial metrics for the company.

Tone

Neutral 50/100

Event

Market update

Published

25 Jun 2026 19:11

Source

TradingView

Amendment: Innate Pharma (NASDAQ: IPHA) shows Novo Nordisk 0% ownership

Novo Nordisk A/S filed an amended Schedule 13G/A, reporting zero beneficial ownership of Innate Pharma's ordinary shares, representing 0.00% of the company. The filing, signed by CFO Karsten Munk Knudsen on June 22, 2026, is an administrative amendment indicating no current discl

Tone

Neutral 50/100

Event

Market update

Published

22 Jun 2026 12:09

Source

Stock Titan

Form 13G Innate Pharma SA For: 22 June By Investing.com

This article from Investing.com announces the filing of Form 13G for Innate Pharma SA (IPH) on June 22. It is a brief news item indicating a regulatory filing has occurred, primarily serving as an update for investors following the company. The content itself is very short and di

Tone

Neutral 50/100

Event

Regulatory and legal

Published

22 Jun 2026 10:10

Source

Investing.com Nigeria

Innate Pharma SA (IPHA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Innate Pharma SA (IPHA), focusing on its P/E, P/B, and Fair Value. The analysis indicates that relevant data for P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. TradingKey provides this information as part of its

Tone

Neutral 50/100

Event

Market update

Published

18 Jun 2026 16:40

Source

TradingKey

Innate Pharma SA (IPHA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Innate Pharma SA (IPHA), detailing various metrics related to volatility, financial risk, and investment risk. It includes data on beta, VaR, maximum drawdown, daily returns, Sharpe Ratio, and turnover rates across different timeframes.

Tone

Neutral 50/100

Event

Macro sensitivity

Published

18 Jun 2026 01:10

Source

TradingKey

Innate Pharma SA (IPHA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Innate Pharma SA (IPHA) has an average analyst rating of "Buy" based on 4 analysts, with a target price of USD 6.00, suggesting a significant upside. The article highlights that relevant earnings per share (EPS), revenue, net profit, and EBIT data have not yet been disclosed by t

Tone

Neutral 50/100

Event

Earnings

Published

18 Jun 2026 01:10

Source

TradingKey

Innate Pharma SA (IPHA) Institutional Confidence

This article from TradingKey provides an overview of Innate Pharma SA's (IPHA) institutional confidence, including its current stock price, market capitalization, and a list of institutional shareholders. Key shareholders like AstraZeneca PLC and Lion Point Capital, L.P. are list

Tone

Neutral 50/100

Event

Market update

Published

18 Jun 2026 01:10

Source

TradingKey

Innate Pharma SA (IPHA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Innate Pharma SA's (IPHA) dividend and stock split history. It states that the company has not distributed any dividends over the past five years and contains no record of historical stock splits. The page also displays current stock quotes an

Tone

Neutral 50/100

Event

Capital return

Published

17 Jun 2026 18:09

Source

TradingKey

Innate Pharma SA (IPHA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey focuses on Innate Pharma SA's (IPHA) revenue breakdown, noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It provides current stock information for IPHA, includ

Tone

Neutral 50/100

Event

Earnings

Published

17 Jun 2026 18:09

Source

TradingKey

IPHA - Innate Pharma ADR Stock Price and Quote

This page provides detailed financial information, stock performance data, and news updates for Innate Pharma ADR (IPHA). It includes key metrics such as market cap, income, sales, and various financial ratios, alongside a comprehensive list of analyst ratings and historical news

Tone

Neutral 50/100

Event

Analyst action

Published

06 Jun 2026 16:12

Source

Finviz

Innate Pharma (Nasdaq: IPHA) outlines 2026 AGM quorum and key pipeline focus

Innate Pharma (Nasdaq: IPHA) announced the voting results of its 2026 Annual General Meeting held on May 21, 2026, in Marseille. All resolutions were voted upon, with a total of 94 votes cast representing 34,921,313 voting rights and achieving a 37,136% quorum. The company also h

Tone

Neutral 50/100

Event

Earnings

Published

22 May 2026 09:40

Source

Stock Titan

Outcome of Innate Pharma’s 2026 Annual General Meeting

Innate Pharma SA announced the voting results of its 2026 Annual General Meeting held on May 21, 2026, in Marseille. All proposed resolutions were approved by shareholders, with details available on the company's website. Innate Pharma is a clinical-stage biotechnology company fo

Tone

Neutral 50/100

Event

Earnings

Published

22 May 2026 09:09

Source

BioSpace

Shareholder turnout and votes at Innate Pharma’s 2026 annual meeting

Innate Pharma SA announced the voting results of its Annual General Meeting (AGM) held on May 21, 2026, in Marseille. All resolutions were passed, with a quorum of 37,136% representing 94 votes cast out of 34,872,293 shares. The company is a clinical-stage biotechnology firm focu

Tone

Neutral 50/100

Event

Earnings

Published

22 May 2026 01:00

Source

Stock Titan

Innate Pharma (Nasdaq: IPHA) to meet investors at Jefferies Global Healthcare Conference 2026

Innate Pharma S.A. (Nasdaq: IPHA), a clinical-stage biotechnology company, announced its executive team will attend the Jefferies Global Healthcare Conference 2026 from June 2-4 in New York for one-on-one investor meetings. The company will showcase its pipeline of antibody-based

Tone

Neutral 50/100

Event

Market update

Published

19 May 2026 09:39

Source

Stock Titan

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Innate Pharma SA, a clinical-stage biotechnology company focused on cancer immunotherapies, announced that its executive team will attend the Jefferies Global Healthcare Conference in New York from June 2–4, 2026. The team will participate in one-on-one investor meetings at the e

Tone

Neutral 50/100

Event

Market update

Published

19 May 2026 07:40

Source

Business Wire

Innate Pharma S.A. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:IPHA) 2026-05-15

This article announces that Innate Pharma S.A. has published its slide deck in conjunction with its 2026 Q1 earnings call. The content is provided by SA Transcripts, which focuses on developing and publishing earnings call transcripts.

Tone

Neutral 50/100

Event

Earnings

Published

16 May 2026 00:09

Source

Seeking Alpha